US biosimilars legislation could take some time to approve, meeting hears
This article was originally published in SRA
Executive Summary
The new political environment in Washington, DC, is favourable towards biosimilars, but getting US biosimilars legislation approved is still likely to be a long haul. This was the message from Juliana Reed, director of the Office of Government Affairs at global pharma and medication delivery company Hospira, who spoke at a meeting on 23-24 April in London that was organised by the European Generic medicines Association.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.